Table 2.
Tumor and treatment characteristics of diabetic cohort stratified by metformin use
| Tumor/treatment characteristic | Metformin (n=1,098) | No metformin (n=818) | P value | Adjusted P valuea |
|---|---|---|---|---|
| American Joint Committee on Cancer stage | 0.45 | NA | ||
| Stage I | 81 (8.3%) | 60 (8.8%) | ||
| Stage II | 241 (24.8%) | 171 (25.1%) | ||
| Stage III | 82 (8.4%) | 68 (10.0%) | ||
| Stage IV | 567 (58.3%) | 382 (56.1%) | ||
| Cancer-directed surgery | 145 (13.3%) | 74 (9.2%) | <0.01 | NA |
| Radiation | 148 (13.6%) | 72 (9.0%) | <0.01 | NA |
| Chemotherapy | 342 (31.2%) | 185 (22.6%) | <0.01 | NA |
| Specific medication | ||||
| Sulfonylurea | 448 (40.8%) | 279 (34.1%) | <0.01 | 0.98 |
| Insulin | 328 (29.9%) | 494 (60.4%) | <0.01 | 0.62 |
| TZD | 288 (26.2%) | 198 (24.2%) | 0.31 | 0.99 |
| Meglitinide | 45 (4.1%) | 56 (6.9%) | <0.01 | 0.98 |
| DPP4 inhibitor | 152 (13.8%) | 87 (10.6%) | 0.04 | 0.98 |
| Survival; months (s.d.) | 5.5 (8.2) | 4.2 (7.2) | <0.01 | NA |
DPP4, dipeptidyl peptidase-4; TZD, thiazolidinediones.
a
Reflects differences between groups after adjusting for propensity score for metformin